

Clinical Trial Protocol

Iranian Registry of Clinical Trials

18 Sep 2026

Comparison of the effectiveness of ACTEMRA (TOCILIZUMAB) and REMICADE (INFLIXIMAB) in patients with Covid19

Protocol summary

Study aim

Determining and comparing the effectiveness of Tocilizumab and Infliximab in patients with Covid19

Design

The clinical trial has two parallel groups, one blind, non-random, phase 2-3 on 40 patients مداخله

Settings and conduct

The intervention is performed for Covid19 patients with severe hospitalization in Shahrekord hospitals. One of the two drugs, tocilizumab and infliximab, are injected into patients at 8 mg and 5 mg per kg body weight, respectively, according to the treating physician. Patients are aware of receiving one of these two drugs but do not know which of the two

Participants/Inclusion and exclusion criteria

1. People aged 25-70 years with Covid19 (based on RT-PCR test for SARS-CoV-19 virus or CT scan criteria) 2. The presence of symptoms indicates the severity of the disease 3. ppd test, and markers of viral hepatitis are negative 4. No pregnancy

Intervention groups

Two groups of patients with severe covid19 disease who received conventional therapies received treatment with tocilizumab and infliximab (one drug in each group).

Main outcome variables

Ferritin; D-dimer; Lactate dehydrogenase; Complete blood cell count; Blood oxygen saturation; Reactive protein c

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20220208053970N1**

Registration date: **2022-03-12, 1400/12/21**

Registration timing: **registered_while_recruiting**

Last update: **2022-03-12, 1400/12/21**

Update count: **0**

Registration date

2022-03-12, 1400/12/21

Registrant information

Name

Amir hossein koohi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 31 3230 5627

Email address

st-kouhi.a@skums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2022-03-12, 1400/12/21

Expected recruitment end date

2022-08-11, 1401/05/20

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparison of the effectiveness of ACTEMRA (TOCILIZUMAB) and REMICADE (INFLIXIMAB) in patients with Covid19

Public title

Effect of Toscilizumab and Infliximab on Covid 19

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

People with Covid 19 (based on RT-PCR test for SARS-CoV-19 virus or CT scan criteria) People between the ages of 25 and 70 Symptoms indicate severe disease (more than 50% of lung involvement in CT or oxygen saturation below 90% or respiratory rate greater than 30 per minute) Elevated CRP, ferritin and other inflammatory markers

Exclusion criteria:

People who test positive for PPD, HCV, HBV and have infections other than Covid 19 infection Pregnancy and pregnancy intention Mild involvement or in the early stages of Covid 19

Age

From **25 years** old to **70 years** old

Gender

Both

Phase

2-3

Groups that have been masked

- Participant
- Care provider

Sample size

Target sample size: **40**

Randomization (investigator's opinion)

Not randomized

Randomization description

Blinding (investigator's opinion)

Single blinded

Blinding description

In this study, patients with Covid19 are divided into two groups and according to the treating physician, one of the drugs Tocilizumab and Infliximab is injected according to the inclusion criteria. In this study, patients are aware and satisfied to receive one of these two drugs, but they are blind to which of these drugs, but the doctor and other research team are aware of which drug to receive by which group.

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Shahrekord University of Medical Sciences (Research Ethics Committee)

Street address

Hajar Hospital, Parastar Ave

City

shahrekord

Province

Chahar-Mahal-va-Bakhtiari

Postal code

8816754633

Approval date

2022-01-25, 1400/11/05

Ethics committee reference number

IR.SKUMS.REC.1400.220

Health conditions studied

1

Description of health condition studied

covid19

ICD-10 code

U10

ICD-10 code description

covid19

Primary outcomes

1

Description

ferritin

Timepoint

Before the intervention and five days after receiving the drug

Method of measurement

Elisa

2

Description

d-dimer

Timepoint

Before the intervention and five days after receiving the drug

Method of measurement

Bio-Lis

3

Description

C-Reactive Protein

Timepoint

Before the intervention and five days after receiving the drug

Method of measurement

Bio-Lis

4

Description

Lactate Dehydrogenase

Timepoint

Before the intervention and five days after receiving the drug

Method of measurement

Bio-Lis

5

Description

complete blood count

Timepoint

Before the intervention and five days after receiving the drug

Method of measurement

sysmex

6

Description

Erythrocyte Sedimentation Rate

Timepoint

Before the intervention and five days after receiving the drug

Method of measurement

Sediman Reader

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group 1: This group of patients with Covid19 who have received standard treatments ,receive tocilizumab brand name ACTEMRA and TEMZIVA from ROCHE PHARMA and ARIOGEN PHARMED factories at a dose of 8 mg / kg in one or two doses two days apart.

Category

Treatment - Drugs

2

Description

Intervention group 2: This group of patients with Covid19 who have received standard treatments, receive an infliximab brand name REMICADE from JANSSEN factory at a dose of 5 mg/kg

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Hajar hospital

Full name of responsible person

Amirhossein Koochi Esfahani

Street address

Parastar Ave

City

Shahrekord

Province

Chahar-Mahal-va-Bakhtiari

Postal code

8816754633

Phone

+98 38 3226 4841

Email

Info@skums.ac.ir

2

Recruitment center

Name of recruitment center

Kashani hospital

Full name of responsible person

Amirhossein koochi esfahani

Street address

Parastar Ave

City

Shahrekord

Province

Chahar-Mahal-va-Bakhtiari

Postal code

۸۸۱۶۷۵۴۹۱۵

Phone

+98 38 3226 4825

Email

Kashani@skums.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Shahre-kord University of Medical Sciences

Full name of responsible person

Esfandiar Heydarian

Street address

Building No. 2, University Headquarters.Kashani Blvd

City

Shahrekord

Province

Chahar-Mahal-va-Bakhtiari

Postal code

۸۸۱۵۷۱۳۴۷۱

Phone

+98 38 3334 2414

Email

vcrt@skums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Shahre-kord University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact

Name of organization / entity
Shahre-kord University of Medical Sciences
Full name of responsible person
Amir hossein Koohi
Position
Resident
Latest degree
Medical doctor
Other areas of specialty/work
Internal Medicine
Street address
121Unit, Ghaem complex, Pars St, Shariati St
City
Shahrekord
Province
Chahar-Mahal-va-Bakhtiari
Postal code
8814658602
Phone
+98 31 3230 5627
Fax
Email
st-kouhi.a@skums.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity
Shahre-kord University of Medical Sciences
Full name of responsible person
Amir hossein Koohi
Position
Resident
Latest degree
Medical doctor
Other areas of specialty/work
Internal Medicine
Street address
121Unit, Ghaem complex, Pars St, Shariati St
City
Shahrekord
Province
Chahar-Mahal-va-Bakhtiari
Postal code
8814658602
Phone
+98 31 3230 5627
Fax
Email
st-kouhi.a@skums.ac.ir

Person responsible for updating data

Contact

Name of organization / entity
Shahre-kord University of Medical Sciences
Full name of responsible person
Amir hossein Koohi
Position
Resident
Latest degree
Medical doctor
Other areas of specialty/work
Internal Medicine
Street address
121Unit, Ghaem complex, Pars St, Shariati St
City
Shahrekord
Province
Chahar-Mahal-va-Bakhtiari
Postal code
8814658602
Phone
+98 31 3230 5627
Fax
Email
st-kouhi.a@skums.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

All data from the study can be shared after being unidentified

When the data will become available and for how long

Access begins in the winter of 1401

To whom data/document is available

The data will be available to researchers and academics

Under which criteria data/document could be used

Access will be possible to assist with future studies and scientific reviews

From where data/document is obtainable

Contact Dr. Amir Hossein Koohi to receive data
amirh1391@gmail.com

What processes are involved for a request to access data/document

After introducing the applicant and stating the purpose of the information request, as well as the commitment not to use it anymore, it can be received via email.

Comments